Systemic infusion of these CAR T cells into immunodeficient mice inhibited the growth of intracranial glioma xenografts in vivo, pointing to podoplanin as a potential target to treat glioblastomas by adoptive immunotherapy. This evidence concerns the gene PDPN and central nervous system cancer.